Yousif Capital Management LLC Sells 370 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Yousif Capital Management LLC cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,808 shares of the company’s stock after selling 370 shares during the quarter. Yousif Capital Management LLC’s holdings in Neurocrine Biosciences were worth $6,167,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Sunbelt Securities Inc. lifted its position in Neurocrine Biosciences by 34.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after acquiring an additional 83 shares in the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after buying an additional 96 shares during the period. Red Spruce Capital LLC lifted its holdings in shares of Neurocrine Biosciences by 0.6% during the 4th quarter. Red Spruce Capital LLC now owns 16,026 shares of the company’s stock valued at $2,112,000 after buying an additional 101 shares during the period. Metis Global Partners LLC lifted its holdings in shares of Neurocrine Biosciences by 4.7% during the 3rd quarter. Metis Global Partners LLC now owns 2,361 shares of the company’s stock valued at $266,000 after buying an additional 106 shares during the period. Finally, Signaturefd LLC lifted its holdings in shares of Neurocrine Biosciences by 5.2% during the 4th quarter. Signaturefd LLC now owns 2,511 shares of the company’s stock valued at $331,000 after buying an additional 125 shares during the period. 92.59% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and set a $147.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 17th. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $140.00 to $170.00 in a research note on Wednesday. Oppenheimer restated an “outperform” rating and issued a $200.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Finally, JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $142.38.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $137.76 on Friday. The company has a market cap of $13.71 billion, a P/E ratio of 56.93 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 1 year low of $89.04 and a 1 year high of $148.37. The firm has a 50-day simple moving average of $136.56 and a two-hundred day simple moving average of $127.69.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The company’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the company posted $0.88 earnings per share. As a group, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current year.

Insider Transactions at Neurocrine Biosciences

In other news, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the transaction, the director now directly owns 29,512 shares of the company’s stock, valued at $3,909,454.64. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the transaction, the director now directly owns 29,512 shares of the company’s stock, valued at $3,909,454.64. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric Benevich sold 19,818 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the transaction, the insider now directly owns 40,778 shares in the company, valued at $5,438,154.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 186,994 shares of company stock valued at $25,806,409. 4.40% of the stock is currently owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.